Lynk Pharmaceuticals completes Phase III enrollment for spondylitis drug
July 15, 2026 | 15:02
Lynk Pharmaceuticals completed patient enrollment on 15 July in its Phase III clinical trial of zemprocitinib for ankylosing spondylitis, advancing its pipeline of immune and inflammatory disease treatments.
Mobile Version